After moving completely virtual, HDYO is excited to host their first ever in person conference for young adults, families and professionals impacted by Huntington’s disease. They are finalizing details, but check out the latest at hdyocongress.org.
MENA Organization for Rare Diseases Annual Meeting will take place in Dubai from 3 to 5 March 2023. During this meeting, experts will deliver the most updated knowledge in presentations and workshops related to rare diseases in various medical fields Ler mais...
The 2022 Huntington’s Disease (HD) Latin American Conference brings together leading international representatives of the HD community – clinicians, scientists, social workers, students, family associations, affected individuals, and at-risk youth. Despite its international character, the conference is and will always Ler mais...
September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts was Ler mais...
Topics presented during the EHDN2022 Plenary Meeting will contain reports on recent advances in HD research (in both basic and clinical sciences). Aside from participating in the plenary and other parallel sessions, attendees will also have the opportunity to meet Ler mais...
This is a story of hope. Sherry Lazaruk and her son, Trevor Strutt, are both diagnosed with Huntington’s Disease. Sherry was diagnosed when she turned 30 and Trevor was diagnosed 5 years ago. Trevor decided to test himself not to Ler mais...
Do you know Dimitri Poffé? Join us on Thursday 14 July at 19:00 h (CET) for a talk with him. This conversation will be held entirely in Spanish via Zoom, and you can register here: https://bit.ly/3byC7xQ Dimitri is a young French Ler mais...
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months Ler mais...
ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company developing a new class of medicines for patients with classical Ler mais...
May Awareness Month 2022 came to an end. Between the webinars, weekends away and Light It Up For HD, there were a lot of initiatives coming from all the different associations. The International Huntington Association and the European Huntington Association Ler mais...
Portuguese 
English 
Arabic 
Spanish